EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Tauk Doujar
Country: Dominica
Language: English (Spanish)
Genre: Education
Published (Last): 4 January 2016
Pages: 485
PDF File Size: 10.94 Mb
ePub File Size: 2.95 Mb
ISBN: 693-7-31863-863-5
Downloads: 65866
Price: Free* [*Free Regsitration Required]
Uploader: Mujora

However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. The aim of the European First Episode Schizophrenia Trial EUFEST eurest to compare treatment with amisulpride, quetiapine, olanzapine eufesst ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with stuudy prior exposure to antipsychotics.

The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug. The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. This outcome is assessed at regular time intervals until 12 months after recruitment.

The principal investigators are Prof. Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

At present, more than patients have been recruited and randomized in the following countries: We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. Intolerance to one of the drugs in this study 4. Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Diagnosis of schizophrenia; 2.

  ARIGO JOHN FULLER PDF

Natural history of schizophrenia. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. Quality of life 6. Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. Evid Based Ment Health. Result of results found for within.

Analysis was by intention to treat. At regular time intervals patients are followed-up until 12 months after recruitment: Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients. Rationale and design of the trial.

Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance. This effort represents the first independently designed trans-European schizophrenia treatment trial.

We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment. Eligibility Participant inclusion criteria 1. Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: Schizophreniform or schizoaffective disorder; 3. Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder 2. This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year.

  ISO 3923-1 PDF

Secondary measures include changes in different uefest of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: Intolerance to one of the drugs in this study; 4.

Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Plain English Summary Not provided at time of registration Trial website http: The Lancet ; Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1.

Home Who are we? Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: Previous Trial Back to results Next Trial. Genetic determinants of response to antipsychotic drugs 9.

Author: admin